09:44 AM EDT, 06/04/2025 (MT Newswires) -- LivaNova ( LIVN ) said Wednesday that it is seeking reconsideration of national Medicare coverage for its VNS Therapy in unipolar patients with treatment-resistant depression.

The company said its request to the US Centers for Medicare and Medicaid Services for coverage reconsideration is supported by the totality of data presented in five critical articles on the Recover clinical study that have recently been published in or accepted by peer-reviewed journals.

The request also includes 24-month clinical outcomes from the study's unipolar group, which demonstrated "substantial" benefit retention and the therapy's long-term durability, LivaNova ( LIVN ) said.

Price: 44.39, Change: +0.28, Percent Change: +0.65